Treatment of Diffuse Large B-Cell Lymphoma

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma, accounting for 30-40% of global cases.
• DLBCL is an aggressive yet potentially curable malignancy characterized by significant clinical and molecular heterogeneity.
• Molecular subtypes identified through gene expression profiling have distinct prognostic and therapeutic implications.

Purpose of the Study:

• To review current treatment strategies for diffuse large B-cell lymphoma.
• To highlight evolving therapeutic approaches for relapsed or refractory disease.
• To discuss the role of molecular characterization and precision medicine in DLBCL management.

Main Methods:

• Review of current clinical guidelines and therapeutic strategies for DLBCL.
• Analysis of data regarding frontline chemoimmunotherapy (e.g., R-CHOP) and its modifications.
• Examination of novel treatment modalities for relapsed/refractory DLBCL, including CAR T-cell therapy and bispecific antibodies.

Main Results:

• Frontline therapy for DLBCL typically involves R-CHOP, with treatment tailored to disease stage, molecular subtype, and patient factors.
• Polatuzumab vedotin substitution for vincristine shows benefit in select patients.
• Chimeric antigen receptor T-cell therapy is a preferred option for early relapse or refractory disease in fit patients.

Conclusions:

• Treatment strategies for DLBCL are increasingly personalized, incorporating molecular profiling and risk stratification.
• Advances in immunotherapy and precision medicine are enhancing outcomes and survival for DLBCL patients.
• Event-free survival at 24 months is a robust surrogate marker for long-term survival in DLBCL.